# Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer

> **NCT02215356** · PHASE2 · UNKNOWN · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Icotinib with concurrent radiotherapy
- **DRUG:** Chemoradiotherapy

## Key facts

- **NCT ID:** NCT02215356
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-08
- **Primary completion:** 2018-08
- **Final completion:** 2019-02
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2014-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02215356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02215356, "Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02215356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*